Besides CRC, METTL3-controlled methylation modification of circRNAs has been implicated in pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and non-small cell lung cancer [43–45], indicating the potential to target METTL3 in cancer treatments. This evidence concerns the gene METTL3 and hepatocellular carcinoma.